Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Lilly

Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade

Amgen stock dipped Monday after an analyst downgraded shares, saying the opportunity for its weight-loss drug is already baked into the stock.

Investors Business Daily

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer

Viking Therapeutics stock is on the rise as the battle to develop new weight-loss drugs heats up. Here's what's at stake for the pharma giants fighting for position.

Investors Business Daily

Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.

Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.

Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Meet the 9 CFOs on Fortune’s 2024 Most Powerful Women list

The list of 100 executives spans the globe.

BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rises On Upsized IPO

BioAge Labs stock rose Thursday on the company's upsized IPO — reflecting enthusiasm for its approach to obesity treatments.

Investors Business Daily

Is Eli Lilly Stock Still a Buy Near All-Time Highs?

With a robust performance, strategic expansions, and strong analyst endorsements, Eli Lilly appears poised for continued growth, making it a compelling investment opportunity.

Snag This Biotech Stock Before November, Here's Why

With Viking Therapeutics making a splash in the weight-loss drug arena, one analyst is encouraging investors to snap up the stock before a November catalyst.

inkl

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly's new CFO is a 23-year company veteran—showing how pharma firms rely on a 'deep bench of qualified talent'

Eli Lilly's new CFO is a 23-year company veteran—showing how pharma firms rely on a 'deep bench of qualified talent'

Lucas Montarce's career path at the company is similar to that of his predecessor, Anat Ashkenazi.

Eli Lilly Names New CFO Amid Weight-loss Drug Expansion Plan

Eli Lilly Names New CFO Amid Weight-loss Drug Expansion Plan

U.S. pharmaceutical giant Eli Lilly named a new chief financial officer on Monday during a critical time for the company's exploding weight-loss drug market.

International Business Times

How Lilly, Novo Could Beat Tesla To The Trillion-Dollar Club; Plus, Nvidia's Battle With Microsoft, Apple

How Lilly, Novo Could Beat Tesla To The Trillion-Dollar Club; Plus, Nvidia's Battle With Microsoft, Apple

Weight-loss drug kingpins Eli Lilly and Novo Nordisk could join the trillion-dollar company club before even Tesla, according to a report.

Investors Business Daily

How Is Eli Lilly’s Stock Performance Compared to Other Drug Manufacturer Stocks?

How Is Eli Lilly’s Stock Performance Compared to Other Drug Manufacturer Stocks?

Eli Lilly has recently outperformed the general drug manufacturers industry, and analysts are highly optimistic about the stock’s prospects.

Former Maryland Resident Sentenced For Congressional Office Harassment

Former Maryland Resident Sentenced For Congressional Office Harassment

Former Maryland resident sentenced to prison for making threatening calls to congressional offices, highlighting the seriousness of threats against elected...

Man sentenced to over 1 year in prison for thousands of harassing calls to congressional offices

Man sentenced to over 1 year in prison for thousands of harassing calls to congressional offices

A former Maryland resident has been sentenced to more than one year behind bars for making thousands of threatening and harassing telephone calls to dozens of congressional offices across the country

The Independent UK

S&P 500 Giants Meta, Eli Lilly Lead 5 Stocks Near Buy Points

S&P 500 Giants Meta, Eli Lilly Lead 5 Stocks Near Buy Points

Meta, Costco and Eli Lilly along with two others are trading near buy points coming out of a week marked by Nvidia earnings.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

3 Mega-Cap Stocks Not Named Nvidia Up More than 40% in 2024

Shares of mega-cap stocks such as Walmart, Meta Platforms, and Eli Lilly have surged over 40% in 2024, outpacing the broader markets by a wide margin.

Investors Business Daily

The 10 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race

The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could get a lift.

Investors Business Daily

Eli Lilly Option Trade Could Return $1,650, If Stock Doesn't Go Haywire

The idea with the trade is that if Eli Lilly stock remains around 950 for the next few weeks, the sold option will decay faster than the bought option.

Popular weight loss drug is getting cheaper

Eli Lilly will now sell cheaper vials of weight loss drug Zepbound in order to meet increased demand.

Get all your
news in one place.

100’s of premium titles.
One news app.

International Business Times

Eli Lilly Launches Discount Anti-Obesity Drug

The company claims the Zepbound doses cost 50% less than competing drugs

Eli Lilly, Palo Alto up; Lowe’s down - Midday stock movers

Here are the stocks making the biggest market moves today.

Investors Business Daily

Eli Lilly, An IBD 50 Stock, Nears Record High On Another Weight-Loss Win

Eli Lilly stock rose Tuesday after Lilly's weight-loss drug significantly cut the risk of developing diabetes over three years.

Up 58% YTD, is Eli Lilly Stock Still a Buy?

The pharmaceutical giant has already delivered massive gains this year, but Wall Street analysts have only gotten more bullish on the maker of Mounjaro and Zepbound.

Analysts reset targets for Eli Lilly shares

Here's what may happen next for the pharma giant's stock price.

Investors Business Daily

Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review

Monday's global sell-off turned into a stock market rally attempt. Palantir, Eli Lilly and Fortinet were among the earnings winners.

Investors Business Daily

Eli Lilly Surges 10% After Diabetes, Weight-Loss Sales Wallop Expectations

Eli Lilly stock rocketed Thursday after its diabetes and weight-loss drugs walloped expectations, leading to a guidance hike.

1 2 3 4 5

People

Mark Zuckerberg

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

236,401 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play